Search details
1.
Pembrolizumab-based first-line treatment for PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: a retrospective analysis.
BMC Cancer
; 24(1): 430, 2024 Apr 08.
Article
in English
| MEDLINE | ID: mdl-38589857
2.
Immune-related toxicity and soluble profile in patients affected by solid tumors: a network approach.
Cancer Immunol Immunother
; 72(7): 2217-2231, 2023 Jul.
Article
in English
| MEDLINE | ID: mdl-36869232
3.
Circulating CD137+ T Cell Levels Are Correlated with Response to Pembrolizumab Treatment in Advanced Head and Neck Cancer Patients.
Int J Mol Sci
; 24(8)2023 Apr 12.
Article
in English
| MEDLINE | ID: mdl-37108276
4.
The role of opioids in cancer response to immunotherapy.
J Transl Med
; 19(1): 119, 2021 03 23.
Article
in English
| MEDLINE | ID: mdl-33757546
5.
Weekly chemotherapy as first line treatment in frail head and neck cancer patients in the immunotherapy era.
J Transl Med
; 19(1): 303, 2021 07 12.
Article
in English
| MEDLINE | ID: mdl-34253248
6.
Induction chemotherapy in nonlaryngeal human papilloma virus-negative high-risk head and neck cancer: a real-world experience.
Anticancer Drugs
; 31(10): 1074-1083, 2020 11.
Article
in English
| MEDLINE | ID: mdl-32932276
7.
Correction: Pembrolizumab-based first-line treatment for PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: a retrospective analysis.
BMC Cancer
; 24(1): 487, 2024 Apr 17.
Article
in English
| MEDLINE | ID: mdl-38632499
8.
Antinuclear antibodies may predict the development of immune-related adverse events in asymptomatic patients treated with immune checkpoint inhibitors: results from a single-center cohort.
Clin Exp Med
; 24(1): 72, 2024 Apr 10.
Article
in English
| MEDLINE | ID: mdl-38598028
9.
PD-L1 testing in metastatic triple negative breast cancer: Results of an Italian survey.
Tumori
; 110(1): 44-48, 2024 Feb.
Article
in English
| MEDLINE | ID: mdl-37726962
10.
Rheumatic Diseases Development in Patients Treated by Anti-PD1 Immune Checkpoint Inhibitors: A Single-Centre Descriptive Study.
Life (Basel)
; 13(4)2023 Mar 25.
Article
in English
| MEDLINE | ID: mdl-37109406
11.
Immune responses and clinical outcomes following the third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in advanced breast cancer patients receiving targeted therapies: a prospective study.
Front Oncol
; 13: 1280416, 2023.
Article
in English
| MEDLINE | ID: mdl-38023235
12.
The Role of the CDK4/6 Inhibitor Ribociclib in Locally Advanced and Oligometastatic Hormone Receptor Positive, Her2 Negative, Advanced Breast Cancer: Case Series and Review of the Literature.
Front Oncol
; 12: 797157, 2022.
Article
in English
| MEDLINE | ID: mdl-35223478
13.
Renal Function Outcomes in Metastatic Non-Small-Cell Lung Carcinoma Patients Treated with Chemotherapy or Immune Checkpoint Inhibitors: An Unexpected Scenario.
Vaccines (Basel)
; 10(5)2022 Apr 24.
Article
in English
| MEDLINE | ID: mdl-35632435
14.
Dental Implant Failure Risk in Post Oncological Patients, a Retrospective Study and Sapienza Head and Neck Unit Decisional Protocol- 7 Years of Follow-Up.
Diagnostics (Basel)
; 12(8)2022 Aug 02.
Article
in English
| MEDLINE | ID: mdl-36010214
15.
The role of immune profile in predicting outcomes in cancer patients treated with immunotherapy.
Front Immunol
; 13: 974087, 2022.
Article
in English
| MEDLINE | ID: mdl-36405727
16.
Genomic and Immune Approach in Platinum Refractory HPV-Negative Head and Neck Squamous Cell Carcinoma Patients Treated with Immunotherapy: A Novel Combined Profile.
Biomedicines
; 10(11)2022 Oct 28.
Article
in English
| MEDLINE | ID: mdl-36359251
17.
The Role of Soluble LAG3 and Soluble Immune Checkpoints Profile in Advanced Head and Neck Cancer: A Pilot Study.
J Pers Med
; 11(7)2021 Jul 10.
Article
in English
| MEDLINE | ID: mdl-34357118
18.
Anti-PD-1 and Anti-PD-L1 in Head and Neck Cancer: A Network Meta-Analysis.
Front Immunol
; 12: 705096, 2021.
Article
in English
| MEDLINE | ID: mdl-34434192
19.
The Impact of Locoregional Treatment on Response to Nivolumab in Advanced Platinum Refractory Head and Neck Cancer: The Need Trial.
Vaccines (Basel)
; 8(2)2020 Apr 20.
Article
in English
| MEDLINE | ID: mdl-32326034
20.
The Agnostic Role of Site of Metastasis in Predicting Outcomes in Cancer Patients Treated with Immunotherapy.
Vaccines (Basel)
; 8(2)2020 Apr 28.
Article
in English
| MEDLINE | ID: mdl-32353934